Biotechnology company Soligenix is progressing its development of SGX945, a promising treatment for painful ulcers associated with Behçet's disease, a rare autoimmune condition that significantly impacts patients' quality of life. The company's phase 2 clinical trial represents a potential advancement in managing this challenging inflammatory disorder.
The open-label study will enroll approximately 25 patients with mild to moderate Behçet's disease, focusing on individuals experiencing active oral and/or genital ulcers. Participants will receive SGX945 as a twice-weekly 4-minute intravenous infusion over four weeks, with researchers evaluating lesion clearance and patient-reported quality of life improvements.
SGX945 contains dusquetide, an innovative innate defense regulator (IDR) that modulates the body's immune response toward anti-inflammatory and tissue healing outcomes. This unique mechanism potentially offers significant relief for patients suffering from a disease currently lacking comprehensive treatment options.
Globally, approximately 1 million people live with Behçet's disease, with around 18,000 cases in the United States and 80,000 in Europe. The market for treating this condition is projected to reach $184.5 million by 2035, underscoring the potential impact of Soligenix's research.
The clinical trial represents a strategic effort to address an unmet medical need, particularly for patients experiencing severe ulcers. By targeting the underlying inflammatory processes, SGX945 could provide a meaningful therapeutic approach for individuals grappling with this challenging autoimmune condition.
